about Details  Shizuki 3A474K Capacitor, Other Wire, Cable & Conduit


  1. Home
  2. about Details  Shizuki 3A474K Capacitor,
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Details about   Shizuki Capacitor, 3A474K
Condition: Seller refurbished: The item has been restored to working order by the eBay seller or a third party. This means the item Custom Bundle: No
Non-Domestic Product: No MPN:

Does Not Apply

Brand:

Shizuki

Modified Item: No
Type: Capacitor UPC:

Does not apply




published on tue nov 09 2021

about Details  Shizuki 3A474K Capacitor, Other Wire, Cable & Conduit

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

about Details  Shizuki 3A474K Capacitor, Other Wire, Cable & Conduit

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS